Treatment of severe pemphigus vulgaris with rituximab

Authors

  • Fatima Bashir Department of Dermatology, Lahore General Hospital, Lahore, Pakistan.
  • Aitisam Waheed Department of Dermatology, Lahore General Hospital, Lahore, Pakistan.
  • Madiha Sanai Department of Dermatology, Lahore General Hospital, Lahore, Pakistan.
  • Ahmad Kazmi Department of Dermatology, Lahore General Hospital, Lahore, Pakistan.
  • Aneela Asghar Department of Dermatology, Lahore General Hospital, Lahore, Pakistan.

DOI:

https://doi.org/10.66344/jpad.31.1.2021.1709

Abstract

Pemphigus vulgaris is an autoimmune skin disease mediated by autoantibodies directed against desmoglein-3 and desmoglein-1 located on keratinocytes. Rituximab, a monoclonal anti-CD20 antibody depleting B-cells, offers an effective treatment possibility for therapy-resistant pemphigus vulgaris. Here, we present a case of 20-year-old female who did not respond sufficiently to conventional treatment with prednisolone, azathioprine, mycophenolate mofetil and intravenous immunoglobulins but underwent almost complete remission after rituximab treatment. It was given as two injections of 500mg each at an interval of two weeks in ICU setting.

Downloads

Published

2021-03-04

How to Cite

1.
Fatima Bashir, Aitisam Waheed, Madiha Sanai, Ahmad Kazmi, Aneela Asghar. Treatment of severe pemphigus vulgaris with rituximab. J Pak Assoc Dermatol [Internet]. 2021Mar.4 [cited 2026Apr.19];31(1):129-32. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1709

Issue

Vol. 31 No. 1 (2021): January - March

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.